| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chorionic Gonadotropin | 31 | 2025 | 77 | 3.860 |
Why?
|
| Menopause | 48 | 2025 | 318 | 3.680 |
Why?
|
| Abortion, Spontaneous | 31 | 2022 | 115 | 3.340 |
Why?
|
| Pregnancy, Ectopic | 33 | 2022 | 53 | 3.270 |
Why?
|
| Pregnancy | 171 | 2025 | 7112 | 2.680 |
Why?
|
| Fertilization in Vitro | 18 | 2025 | 92 | 2.460 |
Why?
|
| Pregnancy Trimester, First | 24 | 2023 | 136 | 2.110 |
Why?
|
| Polycystic Ovary Syndrome | 12 | 2026 | 180 | 1.920 |
Why?
|
| Pregnancy Rate | 13 | 2024 | 69 | 1.800 |
Why?
|
| Vaginal Birth after Cesarean | 9 | 2021 | 27 | 1.760 |
Why?
|
| Hot Flashes | 23 | 2025 | 88 | 1.740 |
Why?
|
| Embryo Transfer | 7 | 2024 | 37 | 1.670 |
Why?
|
| Female | 337 | 2026 | 78137 | 1.580 |
Why?
|
| Adult | 240 | 2026 | 40408 | 1.480 |
Why?
|
| Uterine Hemorrhage | 11 | 2025 | 41 | 1.420 |
Why?
|
| Menstrual Cycle | 12 | 2026 | 140 | 1.410 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 10 | 2022 | 19 | 1.400 |
Why?
|
| Follicle Stimulating Hormone | 33 | 2026 | 249 | 1.310 |
Why?
|
| Anti-Mullerian Hormone | 18 | 2025 | 57 | 1.280 |
Why?
|
| Estradiol | 29 | 2024 | 507 | 1.270 |
Why?
|
| Pregnancy Complications | 19 | 2024 | 586 | 1.270 |
Why?
|
| Depression | 27 | 2026 | 1557 | 1.240 |
Why?
|
| Pregnancy Outcome | 21 | 2024 | 478 | 1.240 |
Why?
|
| Infertility, Female | 12 | 2024 | 111 | 1.210 |
Why?
|
| Sleep Wake Disorders | 6 | 2026 | 308 | 1.190 |
Why?
|
| Postpartum Period | 10 | 2022 | 368 | 1.180 |
Why?
|
| Humans | 348 | 2026 | 144298 | 1.170 |
Why?
|
| Premature Birth | 17 | 2024 | 375 | 1.130 |
Why?
|
| Cohort Studies | 78 | 2024 | 5948 | 1.130 |
Why?
|
| Ovary | 12 | 2025 | 226 | 1.120 |
Why?
|
| Cryopreservation | 4 | 2025 | 106 | 1.110 |
Why?
|
| Misoprostol | 5 | 2022 | 15 | 1.070 |
Why?
|
| Postmenopause | 6 | 2026 | 390 | 1.070 |
Why?
|
| Pre-Eclampsia | 14 | 2023 | 203 | 1.030 |
Why?
|
| Reproduction | 9 | 2021 | 205 | 0.980 |
Why?
|
| Ovulation Induction | 8 | 2025 | 56 | 0.960 |
Why?
|
| Models, Statistical | 9 | 2017 | 675 | 0.960 |
Why?
|
| Longitudinal Studies | 34 | 2026 | 2940 | 0.940 |
Why?
|
| Methotrexate | 8 | 2021 | 231 | 0.930 |
Why?
|
| Women's Health | 4 | 2026 | 307 | 0.920 |
Why?
|
| Cesarean Section | 13 | 2024 | 227 | 0.910 |
Why?
|
| Progesterone | 5 | 2024 | 209 | 0.890 |
Why?
|
| Stress, Psychological | 12 | 2026 | 1148 | 0.890 |
Why?
|
| Gonadal Steroid Hormones | 9 | 2026 | 143 | 0.890 |
Why?
|
| Ovarian Reserve | 7 | 2021 | 17 | 0.870 |
Why?
|
| Premenstrual Syndrome | 9 | 2021 | 33 | 0.860 |
Why?
|
| Reproductive Techniques, Assisted | 4 | 2018 | 43 | 0.830 |
Why?
|
| Embryo Culture Techniques | 1 | 2024 | 11 | 0.820 |
Why?
|
| Risk Factors | 71 | 2024 | 10783 | 0.810 |
Why?
|
| Anxiety | 16 | 2022 | 1114 | 0.800 |
Why?
|
| Hypertension, Pregnancy-Induced | 5 | 2024 | 67 | 0.800 |
Why?
|
| Inhibins | 14 | 2014 | 41 | 0.790 |
Why?
|
| Middle Aged | 121 | 2026 | 35892 | 0.770 |
Why?
|
| Acupuncture Therapy | 2 | 2013 | 21 | 0.760 |
Why?
|
| Young Adult | 79 | 2025 | 14092 | 0.750 |
Why?
|
| Multivariate Analysis | 19 | 2020 | 1537 | 0.730 |
Why?
|
| Aging | 16 | 2024 | 1935 | 0.710 |
Why?
|
| Ultrasonography, Prenatal | 12 | 2021 | 293 | 0.710 |
Why?
|
| Oxytocics | 3 | 2016 | 15 | 0.670 |
Why?
|
| Live Birth | 5 | 2024 | 68 | 0.670 |
Why?
|
| Labor, Induced | 6 | 2020 | 40 | 0.640 |
Why?
|
| Prospective Studies | 49 | 2025 | 7972 | 0.630 |
Why?
|
| Retrospective Studies | 70 | 2025 | 17104 | 0.620 |
Why?
|
| Gestational Age | 18 | 2024 | 980 | 0.610 |
Why?
|
| Perimenopause | 8 | 2025 | 66 | 0.610 |
Why?
|
| Logistic Models | 27 | 2020 | 2112 | 0.610 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 4 | 2015 | 15 | 0.610 |
Why?
|
| Case-Control Studies | 43 | 2025 | 3595 | 0.580 |
Why?
|
| Contraception | 7 | 2022 | 170 | 0.580 |
Why?
|
| Bipolar Disorder | 1 | 2022 | 278 | 0.570 |
Why?
|
| Dehydroepiandrosterone Sulfate | 11 | 2018 | 42 | 0.570 |
Why?
|
| Patient Preference | 5 | 2020 | 226 | 0.570 |
Why?
|
| Placental Lactogen | 1 | 2018 | 17 | 0.570 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 252 | 0.570 |
Why?
|
| Odds Ratio | 21 | 2020 | 1076 | 0.560 |
Why?
|
| Luteinizing Hormone | 16 | 2026 | 190 | 0.550 |
Why?
|
| Fertility Preservation | 5 | 2025 | 53 | 0.550 |
Why?
|
| Neoplasms | 13 | 2021 | 2860 | 0.530 |
Why?
|
| Hormone Replacement Therapy | 2 | 2025 | 106 | 0.530 |
Why?
|
| Body Mass Index | 20 | 2025 | 2417 | 0.520 |
Why?
|
| Surveys and Questionnaires | 33 | 2024 | 6035 | 0.520 |
Why?
|
| Environmental Exposure | 2 | 2025 | 573 | 0.520 |
Why?
|
| Abortion, Induced | 4 | 2022 | 110 | 0.520 |
Why?
|
| Spermatozoa | 4 | 2026 | 107 | 0.520 |
Why?
|
| ADAM Proteins | 2 | 2015 | 63 | 0.520 |
Why?
|
| Cross-Sectional Studies | 31 | 2026 | 5862 | 0.510 |
Why?
|
| Primary Ovarian Insufficiency | 5 | 2021 | 40 | 0.500 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2019 | 880 | 0.500 |
Why?
|
| Antineoplastic Agents | 11 | 2021 | 2194 | 0.490 |
Why?
|
| Sexual Behavior | 5 | 2023 | 492 | 0.490 |
Why?
|
| Predictive Value of Tests | 23 | 2025 | 2113 | 0.490 |
Why?
|
| Executive Function | 9 | 2024 | 460 | 0.480 |
Why?
|
| Risk Assessment | 20 | 2024 | 3680 | 0.470 |
Why?
|
| Pregnanediol | 4 | 2026 | 22 | 0.470 |
Why?
|
| Uterine Neoplasms | 4 | 2018 | 96 | 0.470 |
Why?
|
| Time Factors | 28 | 2025 | 7128 | 0.460 |
Why?
|
| Child Abuse, Sexual | 3 | 2017 | 81 | 0.460 |
Why?
|
| Smoking | 10 | 2022 | 1466 | 0.460 |
Why?
|
| Cancer Survivors | 5 | 2021 | 330 | 0.450 |
Why?
|
| Depressive Disorder | 5 | 2017 | 386 | 0.450 |
Why?
|
| Abortion, Missed | 1 | 2015 | 1 | 0.450 |
Why?
|
| Abortion, Incomplete | 1 | 2015 | 2 | 0.450 |
Why?
|
| Biomarkers | 29 | 2023 | 4248 | 0.440 |
Why?
|
| Pennsylvania | 17 | 2019 | 138 | 0.440 |
Why?
|
| Pregnancy Trimester, Second | 4 | 2019 | 80 | 0.420 |
Why?
|
| Bayes Theorem | 3 | 2015 | 425 | 0.420 |
Why?
|
| Ovarian Follicle | 8 | 2025 | 73 | 0.410 |
Why?
|
| Embryo Implantation | 2 | 2022 | 30 | 0.400 |
Why?
|
| Latin America | 3 | 2024 | 95 | 0.390 |
Why?
|
| Trial of Labor | 5 | 2021 | 18 | 0.390 |
Why?
|
| Breast Neoplasms | 10 | 2017 | 2363 | 0.390 |
Why?
|
| Leiomyoma | 3 | 2018 | 59 | 0.380 |
Why?
|
| Sensitivity and Specificity | 14 | 2020 | 1990 | 0.380 |
Why?
|
| Faculty, Medical | 4 | 2021 | 301 | 0.380 |
Why?
|
| Sexual Dysfunction, Physiological | 4 | 2018 | 74 | 0.380 |
Why?
|
| Infertility | 3 | 2024 | 55 | 0.380 |
Why?
|
| Philadelphia | 16 | 2019 | 55 | 0.380 |
Why?
|
| Premenopause | 7 | 2023 | 123 | 0.370 |
Why?
|
| Labor Stage, First | 3 | 2017 | 5 | 0.370 |
Why?
|
| Hypogonadism | 2 | 2025 | 90 | 0.370 |
Why?
|
| Hydrocortisone | 5 | 2024 | 297 | 0.370 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2020 | 1739 | 0.370 |
Why?
|
| Adolescent | 47 | 2025 | 22370 | 0.360 |
Why?
|
| Parturition | 3 | 2021 | 68 | 0.360 |
Why?
|
| Libido | 7 | 2023 | 24 | 0.360 |
Why?
|
| Infant, Newborn | 22 | 2024 | 6387 | 0.360 |
Why?
|
| Ovarian Neoplasms | 5 | 2024 | 589 | 0.350 |
Why?
|
| Urban Population | 9 | 2017 | 493 | 0.350 |
Why?
|
| Obesity | 9 | 2024 | 3068 | 0.350 |
Why?
|
| Physicians, Women | 3 | 2021 | 88 | 0.350 |
Why?
|
| Linear Models | 12 | 2019 | 845 | 0.350 |
Why?
|
| Cross-Over Studies | 7 | 2024 | 605 | 0.350 |
Why?
|
| Membrane Proteins | 3 | 2015 | 1158 | 0.340 |
Why?
|
| World Health Organization | 2 | 2021 | 104 | 0.340 |
Why?
|
| Age Factors | 22 | 2020 | 3324 | 0.340 |
Why?
|
| Obstetric Labor, Premature | 5 | 2013 | 39 | 0.330 |
Why?
|
| Hypothalamo-Hypophyseal System | 5 | 2024 | 196 | 0.330 |
Why?
|
| Longevity | 2 | 2025 | 173 | 0.330 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2017 | 2134 | 0.330 |
Why?
|
| Obstetric Labor Complications | 4 | 2020 | 38 | 0.330 |
Why?
|
| Abortifacient Agents, Steroidal | 2 | 2021 | 5 | 0.330 |
Why?
|
| Oocyte Retrieval | 4 | 2025 | 12 | 0.330 |
Why?
|
| Follow-Up Studies | 23 | 2022 | 5404 | 0.330 |
Why?
|
| Lisdexamfetamine Dimesylate | 2 | 2024 | 8 | 0.330 |
Why?
|
| Cognition | 8 | 2023 | 1262 | 0.320 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2022 | 187 | 0.310 |
Why?
|
| Placenta | 5 | 2024 | 781 | 0.310 |
Why?
|
| Survivors | 6 | 2014 | 518 | 0.310 |
Why?
|
| Delivery, Obstetric | 7 | 2019 | 161 | 0.310 |
Why?
|
| Sperm Motility | 4 | 2024 | 35 | 0.300 |
Why?
|
| Data Interpretation, Statistical | 4 | 2012 | 368 | 0.300 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2023 | 193 | 0.300 |
Why?
|
| Fetal Macrosomia | 2 | 2024 | 62 | 0.300 |
Why?
|
| Pituitary-Adrenal System | 4 | 2024 | 163 | 0.300 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2025 | 392 | 0.300 |
Why?
|
| Watchful Waiting | 2 | 2021 | 90 | 0.300 |
Why?
|
| United States | 19 | 2026 | 15979 | 0.290 |
Why?
|
| Biometry | 3 | 2015 | 66 | 0.290 |
Why?
|
| Oocytes | 4 | 2025 | 178 | 0.290 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2020 | 32 | 0.290 |
Why?
|
| Mobile Applications | 2 | 2025 | 197 | 0.290 |
Why?
|
| Quality of Life | 7 | 2026 | 3180 | 0.280 |
Why?
|
| Dilatation and Curettage | 4 | 2021 | 12 | 0.280 |
Why?
|
| Fecal Incontinence | 4 | 2020 | 90 | 0.280 |
Why?
|
| Self Report | 5 | 2026 | 867 | 0.280 |
Why?
|
| Promoter Regions, Genetic | 9 | 2009 | 1244 | 0.280 |
Why?
|
| Severity of Illness Index | 14 | 2019 | 2917 | 0.280 |
Why?
|
| Intrauterine Devices, Copper | 2 | 2018 | 7 | 0.270 |
Why?
|
| Intrauterine Device Expulsion | 2 | 2018 | 9 | 0.270 |
Why?
|
| Vasomotor System | 2 | 2025 | 46 | 0.270 |
Why?
|
| Prevalence | 16 | 2025 | 2836 | 0.270 |
Why?
|
| Uterine Myomectomy | 2 | 2018 | 7 | 0.270 |
Why?
|
| Socioeconomic Factors | 15 | 2017 | 1320 | 0.270 |
Why?
|
| Treatment Outcome | 26 | 2024 | 11713 | 0.270 |
Why?
|
| Fetal Growth Retardation | 8 | 2024 | 591 | 0.270 |
Why?
|
| Tryptophan | 3 | 2020 | 175 | 0.270 |
Why?
|
| Reference Values | 9 | 2020 | 793 | 0.270 |
Why?
|
| Follicle Stimulating Hormone, Human | 4 | 2022 | 12 | 0.260 |
Why?
|
| Endometriosis | 4 | 2016 | 57 | 0.260 |
Why?
|
| Factor Analysis, Statistical | 4 | 2017 | 289 | 0.260 |
Why?
|
| ADAM12 Protein | 3 | 2016 | 4 | 0.260 |
Why?
|
| Urinary Incontinence | 6 | 2017 | 64 | 0.260 |
Why?
|
| Temperament | 2 | 2017 | 38 | 0.260 |
Why?
|
| Metabolic Syndrome | 4 | 2013 | 354 | 0.260 |
Why?
|
| Chorionic Villi | 2 | 2024 | 25 | 0.260 |
Why?
|
| Testosterone | 14 | 2018 | 412 | 0.250 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 3 | 2020 | 74 | 0.250 |
Why?
|
| Salpingo-oophorectomy | 2 | 2024 | 19 | 0.250 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2019 | 188 | 0.250 |
Why?
|
| Uterus | 5 | 2022 | 224 | 0.250 |
Why?
|
| Mifepristone | 3 | 2022 | 53 | 0.250 |
Why?
|
| Memory, Short-Term | 3 | 2020 | 271 | 0.240 |
Why?
|
| Maternal Behavior | 2 | 2017 | 83 | 0.240 |
Why?
|
| Hormones | 5 | 2005 | 133 | 0.240 |
Why?
|
| RNA, Small Untranslated | 1 | 2026 | 14 | 0.240 |
Why?
|
| Life Change Events | 2 | 2017 | 146 | 0.240 |
Why?
|
| Dogs | 2 | 2017 | 435 | 0.230 |
Why?
|
| Infant, Small for Gestational Age | 3 | 2016 | 110 | 0.230 |
Why?
|
| Career Mobility | 3 | 2017 | 70 | 0.230 |
Why?
|
| Weight Gain | 3 | 2016 | 557 | 0.230 |
Why?
|
| Postnatal Care | 2 | 2018 | 76 | 0.230 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2025 | 49 | 0.230 |
Why?
|
| Ultrasonography | 9 | 2020 | 773 | 0.230 |
Why?
|
| Therapy, Computer-Assisted | 2 | 2017 | 64 | 0.230 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2017 | 888 | 0.230 |
Why?
|
| Prader-Willi Syndrome | 1 | 2025 | 31 | 0.230 |
Why?
|
| Double-Blind Method | 12 | 2024 | 2032 | 0.220 |
Why?
|
| Anticoagulants | 2 | 2023 | 726 | 0.220 |
Why?
|
| Models, Biological | 3 | 2021 | 1807 | 0.220 |
Why?
|
| Periodontal Diseases | 3 | 2010 | 62 | 0.220 |
Why?
|
| Chorionic Villi Sampling | 1 | 2025 | 4 | 0.220 |
Why?
|
| Prognosis | 13 | 2021 | 4293 | 0.220 |
Why?
|
| Prenatal Care | 8 | 2019 | 304 | 0.220 |
Why?
|
| Male | 45 | 2026 | 72263 | 0.220 |
Why?
|
| Decision Support Techniques | 3 | 2024 | 460 | 0.220 |
Why?
|
| Androgens | 2 | 2019 | 178 | 0.220 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2018 | 64 | 0.220 |
Why?
|
| Reproducibility of Results | 14 | 2024 | 3408 | 0.220 |
Why?
|
| Achievement | 2 | 2017 | 57 | 0.210 |
Why?
|
| Fetus | 4 | 2023 | 800 | 0.210 |
Why?
|
| C-Reactive Protein | 3 | 2023 | 420 | 0.210 |
Why?
|
| Birth Weight | 3 | 2024 | 506 | 0.210 |
Why?
|
| Ovulation | 2 | 2016 | 40 | 0.210 |
Why?
|
| Brain Diseases | 1 | 2005 | 152 | 0.210 |
Why?
|
| Operative Time | 3 | 2020 | 181 | 0.210 |
Why?
|
| Genes, BRCA2 | 2 | 2016 | 33 | 0.210 |
Why?
|
| Environmental Pollutants | 1 | 2026 | 142 | 0.210 |
Why?
|
| Dairying | 2 | 2014 | 12 | 0.210 |
Why?
|
| Genes, BRCA1 | 2 | 2016 | 45 | 0.210 |
Why?
|
| Pregnancy Tests | 2 | 2018 | 10 | 0.210 |
Why?
|
| Recovery of Function | 4 | 2021 | 715 | 0.210 |
Why?
|
| Proportional Hazards Models | 9 | 2019 | 1322 | 0.210 |
Why?
|
| Child Abuse | 3 | 2020 | 548 | 0.210 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2025 | 213 | 0.210 |
Why?
|
| Diabetes, Gestational | 2 | 2020 | 303 | 0.210 |
Why?
|
| Pelvic Organ Prolapse | 3 | 2021 | 62 | 0.210 |
Why?
|
| Patient Satisfaction | 7 | 2021 | 706 | 0.210 |
Why?
|
| Sertraline | 3 | 2021 | 27 | 0.210 |
Why?
|
| Resilience, Psychological | 1 | 2026 | 149 | 0.200 |
Why?
|
| Sterilization, Tubal | 2 | 2019 | 17 | 0.200 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2016 | 579 | 0.200 |
Why?
|
| Cervix Uteri | 3 | 2019 | 50 | 0.200 |
Why?
|
| HELLP Syndrome | 1 | 2023 | 5 | 0.200 |
Why?
|
| Fetal Diseases | 1 | 2005 | 193 | 0.200 |
Why?
|
| Parity | 3 | 2020 | 108 | 0.200 |
Why?
|
| Pelvic Pain | 3 | 2016 | 42 | 0.200 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 1055 | 0.200 |
Why?
|
| Umbilical Arteries | 1 | 2024 | 52 | 0.200 |
Why?
|
| Schools, Medical | 3 | 2017 | 157 | 0.200 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 545 | 0.200 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2025 | 212 | 0.200 |
Why?
|
| Gene Regulatory Networks | 1 | 2026 | 318 | 0.200 |
Why?
|
| Cardiovascular Diseases | 4 | 2020 | 2170 | 0.200 |
Why?
|
| Oximetry | 1 | 2024 | 123 | 0.200 |
Why?
|
| Endometrial Neoplasms | 2 | 2017 | 205 | 0.190 |
Why?
|
| Trophoblasts | 2 | 2022 | 217 | 0.190 |
Why?
|
| Sleep | 2 | 2024 | 889 | 0.190 |
Why?
|
| Heterosexuality | 1 | 2023 | 45 | 0.190 |
Why?
|
| Intrauterine Devices | 2 | 2019 | 29 | 0.180 |
Why?
|
| Contraception Behavior | 3 | 2020 | 108 | 0.180 |
Why?
|
| Choice Behavior | 3 | 2018 | 178 | 0.180 |
Why?
|
| Saliva | 1 | 2024 | 246 | 0.180 |
Why?
|
| Fetal Viability | 1 | 2022 | 3 | 0.180 |
Why?
|
| Spinal Cord Injuries | 1 | 2026 | 240 | 0.180 |
Why?
|
| Ventricular Function, Left | 1 | 2025 | 535 | 0.180 |
Why?
|
| Reflex, Startle | 1 | 2022 | 75 | 0.180 |
Why?
|
| Cognition Disorders | 3 | 2017 | 538 | 0.180 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2022 | 10 | 0.180 |
Why?
|
| Risk-Taking | 1 | 2005 | 324 | 0.180 |
Why?
|
| Particulate Matter | 1 | 2025 | 336 | 0.180 |
Why?
|
| Decidua | 1 | 2022 | 22 | 0.180 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2016 | 83 | 0.180 |
Why?
|
| Cytokines | 4 | 2019 | 2043 | 0.170 |
Why?
|
| Likelihood Functions | 4 | 2017 | 139 | 0.170 |
Why?
|
| Glycodelin | 2 | 2023 | 2 | 0.170 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2014 | 161 | 0.170 |
Why?
|
| Pain | 4 | 2020 | 781 | 0.170 |
Why?
|
| Air Pollution | 1 | 2025 | 318 | 0.170 |
Why?
|
| Premenstrual Dysphoric Disorder | 1 | 2021 | 17 | 0.170 |
Why?
|
| Emigrants and Immigrants | 1 | 2024 | 158 | 0.170 |
Why?
|
| Infant, Premature | 8 | 2010 | 612 | 0.170 |
Why?
|
| Minority Groups | 2 | 2021 | 283 | 0.170 |
Why?
|
| Drug Administration Schedule | 7 | 2010 | 779 | 0.170 |
Why?
|
| Cattle | 2 | 2014 | 971 | 0.170 |
Why?
|
| Endocrine Glands | 1 | 2021 | 14 | 0.170 |
Why?
|
| Hospitals, University | 3 | 2016 | 176 | 0.170 |
Why?
|
| Gonadotropins | 4 | 2015 | 39 | 0.170 |
Why?
|
| Perioperative Period | 2 | 2018 | 70 | 0.170 |
Why?
|
| Fertilization | 2 | 2013 | 43 | 0.160 |
Why?
|
| Smartphone | 2 | 2019 | 100 | 0.160 |
Why?
|
| Postpartum Hemorrhage | 2 | 2019 | 28 | 0.160 |
Why?
|
| Reproductive Behavior | 2 | 2020 | 11 | 0.160 |
Why?
|
| BRCA2 Protein | 2 | 2020 | 67 | 0.160 |
Why?
|
| Pelvic Floor Disorders | 2 | 2019 | 16 | 0.160 |
Why?
|
| Citalopram | 3 | 2014 | 32 | 0.160 |
Why?
|
| Overweight | 1 | 2025 | 606 | 0.160 |
Why?
|
| Tobacco Use Disorder | 1 | 2022 | 218 | 0.160 |
Why?
|
| Genital Diseases, Female | 1 | 2020 | 31 | 0.160 |
Why?
|
| Suicide, Attempted | 1 | 2024 | 421 | 0.160 |
Why?
|
| Manometry | 1 | 2020 | 97 | 0.160 |
Why?
|
| Air Pollutants | 1 | 2025 | 429 | 0.160 |
Why?
|
| Hysterectomy | 2 | 2020 | 137 | 0.160 |
Why?
|
| Rh Isoimmunization | 1 | 2020 | 3 | 0.160 |
Why?
|
| Sweating | 2 | 2018 | 41 | 0.160 |
Why?
|
| Aged | 23 | 2024 | 25901 | 0.160 |
Why?
|
| Oxycodone | 1 | 2020 | 53 | 0.160 |
Why?
|
| Patient Compliance | 4 | 2019 | 587 | 0.160 |
Why?
|
| Vagina | 3 | 2019 | 201 | 0.160 |
Why?
|
| Puerperal Disorders | 1 | 2020 | 37 | 0.160 |
Why?
|
| Stress, Physiological | 2 | 2024 | 446 | 0.160 |
Why?
|
| Fetomaternal Transfusion | 1 | 2020 | 10 | 0.160 |
Why?
|
| Regression Analysis | 9 | 2015 | 997 | 0.160 |
Why?
|
| Diagnosis, Differential | 6 | 2018 | 1501 | 0.160 |
Why?
|
| Lactobacillus | 1 | 2019 | 28 | 0.150 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2025 | 143 | 0.150 |
Why?
|
| Patient Positioning | 1 | 2020 | 69 | 0.150 |
Why?
|
| Uncertainty | 1 | 2020 | 145 | 0.150 |
Why?
|
| Pregnancy, Unplanned | 1 | 2020 | 48 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 4 | 2014 | 1920 | 0.150 |
Why?
|
| Postoperative Complications | 4 | 2020 | 2939 | 0.150 |
Why?
|
| Evidence-Based Medicine | 2 | 2012 | 732 | 0.150 |
Why?
|
| Tertiary Care Centers | 3 | 2019 | 194 | 0.150 |
Why?
|
| Text Messaging | 2 | 2019 | 183 | 0.150 |
Why?
|
| Term Birth | 3 | 2016 | 25 | 0.150 |
Why?
|
| Hysterosalpingography | 2 | 2014 | 8 | 0.150 |
Why?
|
| Nerve Net | 2 | 2020 | 283 | 0.150 |
Why?
|
| ROC Curve | 4 | 2016 | 615 | 0.150 |
Why?
|
| Pain Perception | 1 | 2019 | 24 | 0.150 |
Why?
|
| Levonorgestrel | 1 | 2019 | 34 | 0.150 |
Why?
|
| Mothers | 2 | 2024 | 765 | 0.150 |
Why?
|
| Psychiatric Status Rating Scales | 8 | 2017 | 539 | 0.150 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2020 | 59 | 0.150 |
Why?
|
| Telecommunications | 1 | 2019 | 19 | 0.140 |
Why?
|
| Infant Formula | 1 | 2019 | 71 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2023 | 495 | 0.140 |
Why?
|
| Family Planning Services | 1 | 2020 | 93 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 381 | 0.140 |
Why?
|
| Central Nervous System Stimulants | 2 | 2024 | 185 | 0.140 |
Why?
|
| Uterine Rupture | 4 | 2006 | 8 | 0.140 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2019 | 68 | 0.140 |
Why?
|
| Career Choice | 1 | 2021 | 233 | 0.140 |
Why?
|
| Exercise | 4 | 2017 | 2183 | 0.140 |
Why?
|
| Smoking Cessation | 1 | 2022 | 436 | 0.140 |
Why?
|
| Depression, Postpartum | 1 | 2020 | 123 | 0.140 |
Why?
|
| Congenital Abnormalities | 1 | 1999 | 104 | 0.140 |
Why?
|
| Intrauterine Device Migration | 1 | 2018 | 3 | 0.140 |
Why?
|
| Suicidal Ideation | 1 | 2024 | 575 | 0.140 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1999 | 155 | 0.140 |
Why?
|
| Proteome | 2 | 2022 | 512 | 0.140 |
Why?
|
| Infant, Premature, Diseases | 2 | 2010 | 112 | 0.140 |
Why?
|
| Consumer Health Information | 1 | 2019 | 49 | 0.140 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2019 | 80 | 0.140 |
Why?
|
| Pilot Projects | 7 | 2024 | 1880 | 0.140 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2016 | 72 | 0.140 |
Why?
|
| Waiting Lists | 1 | 2020 | 263 | 0.140 |
Why?
|
| Body Image | 1 | 2019 | 99 | 0.140 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 2 | 2016 | 14 | 0.140 |
Why?
|
| Comorbidity | 7 | 2018 | 1652 | 0.140 |
Why?
|
| Algorithms | 7 | 2019 | 1839 | 0.140 |
Why?
|
| Kisspeptins | 1 | 2018 | 5 | 0.140 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 732 | 0.140 |
Why?
|
| Risk Reduction Behavior | 2 | 2018 | 215 | 0.140 |
Why?
|
| Climacteric | 3 | 2008 | 4 | 0.140 |
Why?
|
| Spermatocidal Agents | 2 | 2015 | 6 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2024 | 912 | 0.130 |
Why?
|
| Research Design | 3 | 2014 | 1128 | 0.130 |
Why?
|
| Maternal Serum Screening Tests | 1 | 2017 | 3 | 0.130 |
Why?
|
| Amenorrhea | 2 | 2025 | 31 | 0.130 |
Why?
|
| Feeding Behavior | 2 | 2017 | 686 | 0.130 |
Why?
|
| Poisson Distribution | 3 | 2012 | 78 | 0.130 |
Why?
|
| Interleukin-6 | 4 | 2023 | 770 | 0.130 |
Why?
|
| Vascular Calcification | 1 | 2019 | 110 | 0.130 |
Why?
|
| Infant, Low Birth Weight | 2 | 2016 | 153 | 0.130 |
Why?
|
| Estrone | 2 | 2016 | 40 | 0.130 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 104 | 0.130 |
Why?
|
| Oxytocin | 2 | 2016 | 51 | 0.130 |
Why?
|
| Cluster Analysis | 1 | 1999 | 516 | 0.130 |
Why?
|
| Mitochondria | 1 | 2024 | 981 | 0.130 |
Why?
|
| Morcellation | 1 | 2017 | 2 | 0.130 |
Why?
|
| Education, Medical | 1 | 2021 | 272 | 0.130 |
Why?
|
| Urinalysis | 2 | 2016 | 80 | 0.130 |
Why?
|
| Terminology as Topic | 3 | 2019 | 254 | 0.130 |
Why?
|
| HSP47 Heat-Shock Proteins | 2 | 2008 | 6 | 0.130 |
Why?
|
| Contraceptive Agents, Female | 2 | 2018 | 80 | 0.130 |
Why?
|
| Administration, Intravaginal | 2 | 2015 | 19 | 0.130 |
Why?
|
| Immunoassay | 2 | 2016 | 105 | 0.130 |
Why?
|
| Child | 13 | 2025 | 22562 | 0.130 |
Why?
|
| Attitude to Health | 4 | 2016 | 431 | 0.130 |
Why?
|
| Coronary Vessels | 1 | 2019 | 246 | 0.130 |
Why?
|
| Blood | 1 | 2017 | 106 | 0.130 |
Why?
|
| Lead Poisoning | 1 | 2017 | 17 | 0.130 |
Why?
|
| Information Storage and Retrieval | 1 | 2018 | 121 | 0.130 |
Why?
|
| Internet | 2 | 2019 | 698 | 0.130 |
Why?
|
| Communication Barriers | 1 | 2019 | 130 | 0.130 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 1098 | 0.130 |
Why?
|
| Anticonvulsants | 4 | 2001 | 242 | 0.130 |
Why?
|
| Bulimia Nervosa | 1 | 2017 | 19 | 0.130 |
Why?
|
| Enoxaparin | 1 | 2017 | 68 | 0.120 |
Why?
|
| Activins | 1 | 2016 | 29 | 0.120 |
Why?
|
| Vacuum Curettage | 1 | 2016 | 4 | 0.120 |
Why?
|
| Binge-Eating Disorder | 1 | 2017 | 30 | 0.120 |
Why?
|
| Mortality | 1 | 2019 | 376 | 0.120 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 187 | 0.120 |
Why?
|
| Doulas | 1 | 2016 | 4 | 0.120 |
Why?
|
| Glucuronides | 1 | 2016 | 18 | 0.120 |
Why?
|
| Data Collection | 3 | 2014 | 632 | 0.120 |
Why?
|
| Pregnancy, Tubal | 1 | 2016 | 5 | 0.120 |
Why?
|
| Follicular Phase | 2 | 2008 | 38 | 0.120 |
Why?
|
| Motor Activity | 2 | 2014 | 723 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 242 | 0.120 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2016 | 15 | 0.120 |
Why?
|
| Mental Health | 2 | 2021 | 790 | 0.120 |
Why?
|
| Fetal Monitoring | 2 | 2014 | 20 | 0.120 |
Why?
|
| Desogestrel | 2 | 2014 | 45 | 0.120 |
Why?
|
| Adrenal Glands | 1 | 2016 | 76 | 0.120 |
Why?
|
| Problem Solving | 1 | 2017 | 156 | 0.120 |
Why?
|
| Cesarean Section, Repeat | 2 | 2006 | 11 | 0.120 |
Why?
|
| Healthy Lifestyle | 1 | 2016 | 37 | 0.120 |
Why?
|
| Pregnanolone | 2 | 2022 | 34 | 0.120 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2010 | 431 | 0.120 |
Why?
|
| Laparoscopy | 2 | 2018 | 475 | 0.120 |
Why?
|
| Smell | 2 | 2015 | 126 | 0.120 |
Why?
|
| Body Composition | 2 | 2013 | 689 | 0.120 |
Why?
|
| Decision Making | 3 | 2020 | 972 | 0.120 |
Why?
|
| Catheterization | 1 | 2016 | 183 | 0.120 |
Why?
|
| Fertility | 2 | 2016 | 166 | 0.120 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2016 | 23 | 0.120 |
Why?
|
| Obesity, Morbid | 1 | 2020 | 288 | 0.120 |
Why?
|
| Feeding and Eating Disorders | 1 | 2018 | 165 | 0.120 |
Why?
|
| Amnion | 4 | 2008 | 31 | 0.120 |
Why?
|
| Health Surveys | 5 | 2011 | 516 | 0.110 |
Why?
|
| Drug Utilization | 2 | 2014 | 167 | 0.110 |
Why?
|
| Breast Feeding | 1 | 2019 | 444 | 0.110 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2007 | 30 | 0.110 |
Why?
|
| Clinical Protocols | 2 | 2014 | 282 | 0.110 |
Why?
|
| Cigarette Smoking | 1 | 2017 | 99 | 0.110 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2008 | 22 | 0.110 |
Why?
|
| Area Under Curve | 4 | 2018 | 328 | 0.110 |
Why?
|
| Pandemics | 1 | 2024 | 1693 | 0.110 |
Why?
|
| Nocturia | 2 | 2020 | 8 | 0.110 |
Why?
|
| Psychotherapy | 1 | 2017 | 189 | 0.110 |
Why?
|
| Fertility Agents, Female | 2 | 2012 | 21 | 0.110 |
Why?
|
| Tablets | 1 | 2015 | 41 | 0.110 |
Why?
|
| Computer Simulation | 4 | 2015 | 1017 | 0.110 |
Why?
|
| Environment | 2 | 2014 | 306 | 0.110 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2015 | 66 | 0.110 |
Why?
|
| Milk | 2 | 2014 | 119 | 0.110 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2012 | 20 | 0.110 |
Why?
|
| Labor Stage, Second | 1 | 2014 | 3 | 0.110 |
Why?
|
| Abdominal Pain | 1 | 2016 | 146 | 0.110 |
Why?
|
| Body Size | 3 | 2014 | 94 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2012 | 45 | 0.110 |
Why?
|
| Brain | 4 | 2020 | 2929 | 0.110 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 182 | 0.110 |
Why?
|
| Signal Transduction | 2 | 2022 | 5182 | 0.110 |
Why?
|
| Dystocia | 1 | 2014 | 12 | 0.110 |
Why?
|
| Dehydroepiandrosterone | 3 | 2005 | 49 | 0.110 |
Why?
|
| Drug Residues | 1 | 2014 | 5 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2019 | 2012 | 0.110 |
Why?
|
| Benzocaine | 1 | 2014 | 1 | 0.100 |
Why?
|
| Placentation | 1 | 2014 | 52 | 0.100 |
Why?
|
| Endometrial Ablation Techniques | 1 | 2014 | 2 | 0.100 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2014 | 30 | 0.100 |
Why?
|
| Neuropsychological Tests | 5 | 2020 | 1134 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2017 | 640 | 0.100 |
Why?
|
| Chorioamnionitis | 3 | 2014 | 49 | 0.100 |
Why?
|
| Food Contamination | 1 | 2014 | 55 | 0.100 |
Why?
|
| Peru | 4 | 2014 | 62 | 0.100 |
Why?
|
| Uterine Diseases | 3 | 2009 | 18 | 0.100 |
Why?
|
| Memory | 2 | 2013 | 296 | 0.100 |
Why?
|
| Mexico | 2 | 2025 | 234 | 0.100 |
Why?
|
| Incidence | 9 | 2017 | 2886 | 0.100 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 8265 | 0.100 |
Why?
|
| Pregnancy Proteins | 1 | 2014 | 35 | 0.100 |
Why?
|
| Medical Records | 3 | 2010 | 190 | 0.100 |
Why?
|
| Menorrhagia | 1 | 2014 | 22 | 0.100 |
Why?
|
| Carcinoma, Lobular | 1 | 2014 | 55 | 0.100 |
Why?
|
| Proteinuria | 1 | 2014 | 103 | 0.100 |
Why?
|
| Animal Husbandry | 1 | 2014 | 37 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 88 | 0.100 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2013 | 10 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2017 | 425 | 0.100 |
Why?
|
| Sex Factors | 4 | 2024 | 2103 | 0.100 |
Why?
|
| Betamethasone | 2 | 2010 | 21 | 0.100 |
Why?
|
| Job Satisfaction | 2 | 2012 | 235 | 0.100 |
Why?
|
| Matrix Metalloproteinase 8 | 2 | 2004 | 8 | 0.100 |
Why?
|
| Patient Education as Topic | 2 | 2016 | 771 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 3 | 2019 | 408 | 0.100 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 66 | 0.100 |
Why?
|
| Calcium | 1 | 2019 | 1174 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2020 | 1763 | 0.100 |
Why?
|
| Health Status | 3 | 2011 | 833 | 0.090 |
Why?
|
| Device Removal | 1 | 2014 | 142 | 0.090 |
Why?
|
| Taxoids | 1 | 2013 | 115 | 0.090 |
Why?
|
| Cystitis, Interstitial | 1 | 2012 | 20 | 0.090 |
Why?
|
| BCG Vaccine | 1 | 2012 | 27 | 0.090 |
Why?
|
| Headache | 2 | 2018 | 150 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2019 | 850 | 0.090 |
Why?
|
| Leadership | 1 | 2017 | 399 | 0.090 |
Why?
|
| Pain Management | 1 | 2016 | 407 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 1314 | 0.090 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2012 | 4 | 0.090 |
Why?
|
| Memory Disorders | 1 | 2013 | 194 | 0.090 |
Why?
|
| Weight Loss | 1 | 2018 | 838 | 0.090 |
Why?
|
| Communication | 1 | 2019 | 968 | 0.090 |
Why?
|
| Personnel Turnover | 1 | 2012 | 41 | 0.090 |
Why?
|
| Organizational Policy | 1 | 2012 | 76 | 0.090 |
Why?
|
| Chemistry, Clinical | 1 | 2012 | 5 | 0.090 |
Why?
|
| Monte Carlo Method | 1 | 2012 | 153 | 0.090 |
Why?
|
| Creatinine | 1 | 2014 | 509 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2013 | 133 | 0.090 |
Why?
|
| Proteomics | 3 | 2011 | 1182 | 0.090 |
Why?
|
| Child Development | 1 | 2017 | 482 | 0.090 |
Why?
|
| Gravidity | 1 | 2011 | 7 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2013 | 254 | 0.090 |
Why?
|
| Morbidity | 4 | 2018 | 322 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2012 | 57 | 0.090 |
Why?
|
| Social Class | 2 | 2010 | 265 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 1142 | 0.090 |
Why?
|
| Genetic Variation | 3 | 2014 | 982 | 0.090 |
Why?
|
| Smokers | 2 | 2022 | 137 | 0.090 |
Why?
|
| Factor V | 2 | 2009 | 26 | 0.090 |
Why?
|
| Mood Disorders | 3 | 2020 | 140 | 0.090 |
Why?
|
| Labor Pain | 2 | 2009 | 12 | 0.090 |
Why?
|
| Nitriles | 1 | 2013 | 204 | 0.090 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 23 | 0.090 |
Why?
|
| Attention | 1 | 2015 | 458 | 0.090 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 2321 | 0.090 |
Why?
|
| Insemination, Artificial, Heterologous | 1 | 2011 | 2 | 0.090 |
Why?
|
| Biostatistics | 1 | 2011 | 18 | 0.090 |
Why?
|
| Thyroid Hormones | 1 | 2012 | 68 | 0.090 |
Why?
|
| Puerperal Infection | 1 | 2011 | 5 | 0.090 |
Why?
|
| Hypothyroidism | 1 | 2012 | 67 | 0.090 |
Why?
|
| Lymphedema | 1 | 2011 | 22 | 0.090 |
Why?
|
| Povidone-Iodine | 1 | 2011 | 11 | 0.090 |
Why?
|
| Triazoles | 1 | 2013 | 184 | 0.080 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2011 | 49 | 0.080 |
Why?
|
| Thyroid Gland | 1 | 2012 | 88 | 0.080 |
Why?
|
| Menarche | 2 | 2009 | 52 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2014 | 374 | 0.080 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2011 | 63 | 0.080 |
Why?
|
| Disintegrins | 1 | 2011 | 6 | 0.080 |
Why?
|
| Telemedicine | 2 | 2019 | 957 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2025 | 2571 | 0.080 |
Why?
|
| Databases, Factual | 5 | 2017 | 1489 | 0.080 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2011 | 40 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 325 | 0.080 |
Why?
|
| Fallopian Tube Diseases | 3 | 2009 | 6 | 0.080 |
Why?
|
| Dental Scaling | 1 | 2010 | 4 | 0.080 |
Why?
|
| Angiogenic Proteins | 1 | 2010 | 14 | 0.080 |
Why?
|
| Treatment Failure | 4 | 2014 | 364 | 0.080 |
Why?
|
| Crime | 2 | 2014 | 59 | 0.080 |
Why?
|
| Gene Frequency | 6 | 2010 | 480 | 0.080 |
Why?
|
| Prenatal Diagnosis | 1 | 2012 | 195 | 0.080 |
Why?
|
| Animals | 15 | 2024 | 37800 | 0.080 |
Why?
|
| Oral Hygiene | 1 | 2010 | 15 | 0.080 |
Why?
|
| Editorial Policies | 1 | 2011 | 46 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1565 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 139 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2011 | 175 | 0.080 |
Why?
|
| Chi-Square Distribution | 4 | 2017 | 524 | 0.080 |
Why?
|
| Mother-Child Relations | 2 | 2024 | 132 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 540 | 0.080 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 771 | 0.080 |
Why?
|
| Vaginosis, Bacterial | 1 | 2010 | 10 | 0.080 |
Why?
|
| Bias | 1 | 2011 | 197 | 0.080 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 173 | 0.080 |
Why?
|
| Altitude | 1 | 2014 | 473 | 0.080 |
Why?
|
| Protein Kinase C-alpha | 1 | 2010 | 37 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2009 | 21 | 0.080 |
Why?
|
| Tissue Donors | 2 | 2011 | 412 | 0.080 |
Why?
|
| Triage | 1 | 2012 | 249 | 0.080 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2009 | 9 | 0.080 |
Why?
|
| Nicotine | 2 | 2022 | 333 | 0.080 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2000 | 32 | 0.080 |
Why?
|
| Antidepressive Agents | 1 | 2011 | 247 | 0.080 |
Why?
|
| Semen Analysis | 2 | 2024 | 14 | 0.080 |
Why?
|
| Diagnosis-Related Groups | 1 | 2009 | 35 | 0.080 |
Why?
|
| Contraceptive Agents | 2 | 2022 | 65 | 0.080 |
Why?
|
| Aromatase Inhibitors | 1 | 2010 | 74 | 0.080 |
Why?
|
| Polymorphism, Genetic | 2 | 2002 | 612 | 0.080 |
Why?
|
| Cocaine-Related Disorders | 3 | 2008 | 132 | 0.070 |
Why?
|
| Mutation | 5 | 2020 | 4068 | 0.070 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2009 | 40 | 0.070 |
Why?
|
| HIV Infections | 2 | 2019 | 3148 | 0.070 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2009 | 19 | 0.070 |
Why?
|
| Uterine Prolapse | 1 | 2009 | 14 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2011 | 397 | 0.070 |
Why?
|
| Occupational Exposure | 2 | 2005 | 353 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2013 | 643 | 0.070 |
Why?
|
| Carcinoma | 1 | 2010 | 224 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 100 | 0.070 |
Why?
|
| Educational Status | 4 | 2019 | 463 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2023 | 1206 | 0.070 |
Why?
|
| Contraceptive Devices, Female | 1 | 2008 | 14 | 0.070 |
Why?
|
| Haplotypes | 2 | 2015 | 490 | 0.070 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2008 | 18 | 0.070 |
Why?
|
| Enzymes | 1 | 2009 | 65 | 0.070 |
Why?
|
| Sample Size | 2 | 2025 | 120 | 0.070 |
Why?
|
| Affect | 4 | 2018 | 322 | 0.070 |
Why?
|
| Pinus | 1 | 2008 | 17 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 2019 | 318 | 0.070 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 265 | 0.070 |
Why?
|
| Alzheimer Disease | 1 | 2015 | 618 | 0.070 |
Why?
|
| Consensus | 1 | 2010 | 475 | 0.070 |
Why?
|
| Vitis | 1 | 2008 | 28 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2010 | 246 | 0.070 |
Why?
|
| 5' Flanking Region | 1 | 2008 | 9 | 0.070 |
Why?
|
| Violence | 2 | 2003 | 279 | 0.070 |
Why?
|
| Domestic Violence | 2 | 2017 | 51 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 1359 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1955 | 0.070 |
Why?
|
| Fallopian Tubes | 3 | 2019 | 31 | 0.070 |
Why?
|
| Phytotherapy | 1 | 2008 | 74 | 0.070 |
Why?
|
| Base Pairing | 1 | 2008 | 65 | 0.070 |
Why?
|
| Estrogens | 2 | 2025 | 364 | 0.070 |
Why?
|
| Parvoviridae Infections | 1 | 2007 | 12 | 0.070 |
Why?
|
| Olfactory Pathways | 1 | 2008 | 38 | 0.070 |
Why?
|
| Abortion, Threatened | 1 | 2007 | 2 | 0.070 |
Why?
|
| Seeds | 1 | 2008 | 74 | 0.070 |
Why?
|
| Maternal Age | 4 | 2010 | 126 | 0.070 |
Why?
|
| Nerve Regeneration | 1 | 2008 | 58 | 0.070 |
Why?
|
| Extracellular Space | 1 | 2008 | 119 | 0.070 |
Why?
|
| CA-125 Antigen | 1 | 2007 | 13 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 294 | 0.070 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 329 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2008 | 190 | 0.060 |
Why?
|
| Irritable Mood | 1 | 2008 | 50 | 0.060 |
Why?
|
| Endometrium | 1 | 2007 | 59 | 0.060 |
Why?
|
| Mice | 8 | 2024 | 18218 | 0.060 |
Why?
|
| Inflammation | 3 | 2023 | 2862 | 0.060 |
Why?
|
| Length of Stay | 3 | 2022 | 1338 | 0.060 |
Why?
|
| Sarcoma | 1 | 2009 | 203 | 0.060 |
Why?
|
| Developing Countries | 2 | 2023 | 317 | 0.060 |
Why?
|
| Olfaction Disorders | 1 | 2008 | 70 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2014 | 712 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 2010 | 441 | 0.060 |
Why?
|
| Dependovirus | 1 | 2007 | 77 | 0.060 |
Why?
|
| Sexuality | 1 | 2007 | 31 | 0.060 |
Why?
|
| Observer Variation | 3 | 2016 | 353 | 0.060 |
Why?
|
| Testicular Hormones | 1 | 2006 | 8 | 0.060 |
Why?
|
| Statistics as Topic | 3 | 2014 | 284 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2009 | 233 | 0.060 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 3 | 2012 | 6 | 0.060 |
Why?
|
| Echocardiography | 2 | 2020 | 644 | 0.060 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2008 | 107 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 651 | 0.060 |
Why?
|
| Cystic Fibrosis | 1 | 2016 | 1161 | 0.060 |
Why?
|
| Drug Implants | 2 | 2018 | 83 | 0.060 |
Why?
|
| Radiotherapy | 2 | 2020 | 205 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2024 | 776 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1263 | 0.060 |
Why?
|
| Personality | 1 | 2007 | 128 | 0.060 |
Why?
|
| Phthalic Acids | 1 | 2026 | 41 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2016 | 2326 | 0.060 |
Why?
|
| Alcohol Drinking | 3 | 2009 | 823 | 0.060 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2019 | 57 | 0.060 |
Why?
|
| Puberty, Delayed | 1 | 2025 | 10 | 0.060 |
Why?
|
| Receptors, Cell Surface | 2 | 2010 | 370 | 0.060 |
Why?
|
| Brain Mapping | 2 | 2020 | 535 | 0.060 |
Why?
|
| Entropy | 1 | 2025 | 44 | 0.060 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 88 | 0.060 |
Why?
|
| Nerve Growth Factors | 1 | 2005 | 78 | 0.060 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2005 | 24 | 0.060 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 500 | 0.060 |
Why?
|
| Phenols | 1 | 2026 | 107 | 0.060 |
Why?
|
| Walking | 1 | 2010 | 542 | 0.060 |
Why?
|
| Microtubule Proteins | 1 | 2005 | 13 | 0.060 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2025 | 74 | 0.060 |
Why?
|
| Infertility, Male | 1 | 2005 | 74 | 0.060 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2005 | 52 | 0.060 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2018 | 141 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2005 | 139 | 0.050 |
Why?
|
| Health Personnel | 2 | 2024 | 744 | 0.050 |
Why?
|
| Menstruation | 1 | 2005 | 40 | 0.050 |
Why?
|
| Infant | 4 | 2024 | 10011 | 0.050 |
Why?
|
| Brazil | 1 | 2025 | 182 | 0.050 |
Why?
|
| Th2 Cells | 1 | 2005 | 171 | 0.050 |
Why?
|
| Epididymis | 1 | 2024 | 14 | 0.050 |
Why?
|
| Spermatogenesis | 1 | 2005 | 91 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2006 | 353 | 0.050 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2005 | 62 | 0.050 |
Why?
|
| Rural Population | 3 | 2014 | 654 | 0.050 |
Why?
|
| Fluorocarbons | 1 | 2026 | 119 | 0.050 |
Why?
|
| Blood Cell Count | 2 | 2020 | 54 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2020 | 3879 | 0.050 |
Why?
|
| Cell Respiration | 1 | 2024 | 105 | 0.050 |
Why?
|
| Testis | 1 | 2005 | 162 | 0.050 |
Why?
|
| Abortion, Habitual | 1 | 2004 | 4 | 0.050 |
Why?
|
| Efficiency | 2 | 2017 | 104 | 0.050 |
Why?
|
| Cell Death | 1 | 2005 | 382 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 194 | 0.050 |
Why?
|
| Electronics | 1 | 2024 | 69 | 0.050 |
Why?
|
| Bolivia | 1 | 2023 | 61 | 0.050 |
Why?
|
| Astrocytes | 1 | 2005 | 228 | 0.050 |
Why?
|
| Intensive Care Units, Neonatal | 3 | 2013 | 287 | 0.050 |
Why?
|
| Obstetrics | 2 | 2018 | 175 | 0.050 |
Why?
|
| Random Allocation | 2 | 2020 | 364 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2005 | 188 | 0.050 |
Why?
|
| Technology | 1 | 2024 | 95 | 0.050 |
Why?
|
| Thrombophilia | 1 | 2004 | 88 | 0.050 |
Why?
|
| Ultrasonography, Doppler | 1 | 2024 | 126 | 0.050 |
Why?
|
| Superoxides | 1 | 2004 | 199 | 0.050 |
Why?
|
| Probability | 3 | 2010 | 308 | 0.050 |
Why?
|
| Women | 1 | 2003 | 50 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 668 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2016 | 553 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2008 | 664 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2003 | 144 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 5954 | 0.050 |
Why?
|
| Acoustics | 1 | 2022 | 48 | 0.050 |
Why?
|
| Health Behavior | 2 | 2010 | 786 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2024 | 288 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2008 | 925 | 0.040 |
Why?
|
| Food Preferences | 1 | 2003 | 126 | 0.040 |
Why?
|
| Recurrence | 3 | 2014 | 1134 | 0.040 |
Why?
|
| Selection Bias | 1 | 2002 | 38 | 0.040 |
Why?
|
| Cell Count | 2 | 2014 | 320 | 0.040 |
Why?
|
| Extracellular Vesicles | 1 | 2024 | 170 | 0.040 |
Why?
|
| Epidemiologic Studies | 1 | 2002 | 68 | 0.040 |
Why?
|
| Vitamins | 1 | 2023 | 176 | 0.040 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2001 | 10 | 0.040 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2001 | 38 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2002 | 130 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2004 | 335 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 1044 | 0.040 |
Why?
|
| Culture | 2 | 2012 | 125 | 0.040 |
Why?
|
| Sex Offenses | 1 | 2024 | 195 | 0.040 |
Why?
|
| United Kingdom | 2 | 2014 | 337 | 0.040 |
Why?
|
| Crime Victims | 1 | 2003 | 129 | 0.040 |
Why?
|
| Amniotic Fluid | 1 | 2001 | 79 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2024 | 1102 | 0.040 |
Why?
|
| Infant Food | 1 | 2001 | 64 | 0.040 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2022 | 71 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2022 | 350 | 0.040 |
Why?
|
| Adaptation, Psychological | 2 | 2016 | 713 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2012 | 331 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 2021 | 124 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2001 | 268 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 212 | 0.040 |
Why?
|
| Reward | 1 | 2023 | 245 | 0.040 |
Why?
|
| Prescriptions | 1 | 2020 | 75 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2023 | 288 | 0.040 |
Why?
|
| Semen | 1 | 2000 | 24 | 0.040 |
Why?
|
| Lipids | 2 | 2009 | 702 | 0.040 |
Why?
|
| Registries | 1 | 2009 | 2389 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2022 | 199 | 0.040 |
Why?
|
| Ibuprofen | 1 | 2020 | 84 | 0.040 |
Why?
|
| Patient Selection | 3 | 2014 | 721 | 0.040 |
Why?
|
| Fatigue | 1 | 2022 | 363 | 0.040 |
Why?
|
| Cervical Length Measurement | 1 | 2019 | 5 | 0.040 |
Why?
|
| Cues | 1 | 2022 | 326 | 0.040 |
Why?
|
| Interpersonal Relations | 1 | 2003 | 398 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2012 | 93 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 81 | 0.040 |
Why?
|
| Women's Health Services | 1 | 2000 | 15 | 0.040 |
Why?
|
| Diagnostic Errors | 2 | 2012 | 177 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 495 | 0.040 |
Why?
|
| Behavior | 1 | 2020 | 90 | 0.040 |
Why?
|
| Pesticides | 1 | 2000 | 60 | 0.040 |
Why?
|
| Pressure | 1 | 2020 | 224 | 0.040 |
Why?
|
| Diet | 2 | 2018 | 1270 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2020 | 163 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 454 | 0.040 |
Why?
|
| Fenfluramine | 1 | 1999 | 17 | 0.040 |
Why?
|
| Appetite Depressants | 1 | 1999 | 19 | 0.040 |
Why?
|
| Phentermine | 1 | 1999 | 14 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2005 | 675 | 0.040 |
Why?
|
| Child, Preschool | 4 | 2025 | 11767 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 832 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2020 | 90 | 0.040 |
Why?
|
| Fingers | 1 | 2000 | 107 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2009 | 4102 | 0.040 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 126 | 0.040 |
Why?
|
| Heart Valves | 1 | 1999 | 43 | 0.040 |
Why?
|
| Endometritis | 1 | 2019 | 4 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 1999 | 89 | 0.040 |
Why?
|
| Sterilization, Reproductive | 1 | 2018 | 8 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 637 | 0.040 |
Why?
|
| Forecasting | 1 | 2021 | 391 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2019 | 114 | 0.040 |
Why?
|
| Electronic Mail | 1 | 2019 | 59 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 768 | 0.040 |
Why?
|
| Rupture | 1 | 2019 | 91 | 0.040 |
Why?
|
| Transportation | 1 | 2019 | 54 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2019 | 65 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 238 | 0.030 |
Why?
|
| Authorship | 1 | 2019 | 49 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2002 | 733 | 0.030 |
Why?
|
| Long-Acting Reversible Contraception | 1 | 2018 | 34 | 0.030 |
Why?
|
| Health Communication | 1 | 2019 | 54 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2020 | 311 | 0.030 |
Why?
|
| Histones | 1 | 2004 | 663 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2018 | 96 | 0.030 |
Why?
|
| Chemical Industry | 1 | 1998 | 9 | 0.030 |
Why?
|
| Placebos | 2 | 2014 | 193 | 0.030 |
Why?
|
| Genotype | 3 | 2010 | 1843 | 0.030 |
Why?
|
| Petroleum | 1 | 1998 | 10 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2021 | 370 | 0.030 |
Why?
|
| Neutrophils | 1 | 2004 | 1115 | 0.030 |
Why?
|
| Heart Valve Diseases | 1 | 1999 | 150 | 0.030 |
Why?
|
| Laparotomy | 1 | 2018 | 112 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2018 | 95 | 0.030 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2017 | 6 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 966 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2017 | 25 | 0.030 |
Why?
|
| Device Approval | 1 | 2017 | 19 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2019 | 157 | 0.030 |
Why?
|
| Neuronal Plasticity | 1 | 2020 | 305 | 0.030 |
Why?
|
| Luteal Phase | 2 | 2009 | 46 | 0.030 |
Why?
|
| Nomograms | 1 | 2017 | 59 | 0.030 |
Why?
|
| Emotions | 1 | 2022 | 575 | 0.030 |
Why?
|
| California | 1 | 2019 | 471 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2019 | 194 | 0.030 |
Why?
|
| Patient Health Questionnaire | 1 | 2017 | 40 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 427 | 0.030 |
Why?
|
| Child of Impaired Parents | 1 | 2017 | 38 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2007 | 1728 | 0.030 |
Why?
|
| Physicians, Family | 1 | 2018 | 173 | 0.030 |
Why?
|
| Work-Life Balance | 1 | 2017 | 22 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 195 | 0.030 |
Why?
|
| Parents | 1 | 2005 | 1393 | 0.030 |
Why?
|
| Family Conflict | 1 | 2017 | 43 | 0.030 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2016 | 33 | 0.030 |
Why?
|
| Decision Trees | 2 | 2008 | 79 | 0.030 |
Why?
|
| Contraceptives, Oral | 1 | 2016 | 37 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 390 | 0.030 |
Why?
|
| Radioimmunoassay | 2 | 2007 | 165 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 266 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2016 | 44 | 0.030 |
Why?
|
| Perinatal Care | 1 | 2017 | 61 | 0.030 |
Why?
|
| Diet Records | 1 | 2016 | 84 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 332 | 0.030 |
Why?
|
| Heterozygote | 1 | 2017 | 313 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 559 | 0.030 |
Why?
|
| Condoms | 1 | 2016 | 101 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 1075 | 0.030 |
Why?
|
| Age Distribution | 2 | 2008 | 402 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 1998 | 165 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2010 | 2348 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2004 | 1726 | 0.030 |
Why?
|
| Feedback | 1 | 2016 | 181 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2019 | 401 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 461 | 0.030 |
Why?
|
| Vitamin D | 1 | 2019 | 400 | 0.030 |
Why?
|
| Corticosterone | 1 | 2016 | 242 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 537 | 0.030 |
Why?
|
| Telephone | 1 | 2016 | 176 | 0.030 |
Why?
|
| Plant Preparations | 2 | 2008 | 37 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 328 | 0.030 |
Why?
|
| Feces | 1 | 2018 | 513 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 623 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 2081 | 0.030 |
Why?
|
| Serotonin | 1 | 2017 | 293 | 0.030 |
Why?
|
| Spatial Memory | 1 | 2015 | 28 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 359 | 0.030 |
Why?
|
| Wechsler Scales | 1 | 2015 | 59 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 1784 | 0.030 |
Why?
|
| Labor, Obstetric | 2 | 2005 | 67 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2017 | 613 | 0.030 |
Why?
|
| Fetal Distress | 1 | 2014 | 14 | 0.030 |
Why?
|
| Apolipoprotein E4 | 1 | 2015 | 41 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2017 | 888 | 0.030 |
Why?
|
| Epilepsy | 1 | 1999 | 386 | 0.030 |
Why?
|
| Personality Inventory | 2 | 2006 | 133 | 0.030 |
Why?
|
| Health Literacy | 1 | 2017 | 184 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2017 | 308 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 2589 | 0.030 |
Why?
|
| Leisure Activities | 1 | 2014 | 30 | 0.030 |
Why?
|
| Wounds and Injuries | 2 | 2000 | 944 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2014 | 20 | 0.030 |
Why?
|
| Placenta Growth Factor | 1 | 2014 | 26 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 371 | 0.030 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2014 | 12 | 0.030 |
Why?
|
| Cyclohexanols | 1 | 2014 | 10 | 0.030 |
Why?
|
| Dietary Supplements | 2 | 2014 | 575 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2015 | 136 | 0.030 |
Why?
|
| Health | 1 | 2014 | 80 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2017 | 517 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2020 | 750 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 551 | 0.030 |
Why?
|
| Heparin | 1 | 2015 | 242 | 0.030 |
Why?
|
| Gonadotropins, Pituitary | 1 | 2013 | 22 | 0.020 |
Why?
|
| Yoga | 1 | 2014 | 31 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 147 | 0.020 |
Why?
|
| Quality Control | 1 | 2014 | 163 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 188 | 0.020 |
Why?
|
| Checklist | 1 | 2014 | 110 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 98 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2017 | 409 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2019 | 762 | 0.020 |
Why?
|
| Income | 1 | 2014 | 200 | 0.020 |
Why?
|
| Mental Recall | 1 | 2015 | 222 | 0.020 |
Why?
|
| Uterine Artery | 1 | 2014 | 74 | 0.020 |
Why?
|
| Hospitalization | 2 | 2019 | 2440 | 0.020 |
Why?
|
| Medicaid | 1 | 2017 | 464 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 847 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 2 | 2005 | 84 | 0.020 |
Why?
|
| Agriculture | 1 | 2013 | 103 | 0.020 |
Why?
|
| Follicular Atresia | 1 | 2012 | 4 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 1999 | 743 | 0.020 |
Why?
|
| Hospital Units | 1 | 2012 | 32 | 0.020 |
Why?
|
| Birth Rate | 1 | 2012 | 28 | 0.020 |
Why?
|
| Micromanipulation | 1 | 2012 | 14 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2012 | 5 | 0.020 |
Why?
|
| Alleles | 2 | 2006 | 881 | 0.020 |
Why?
|
| Thyroxine-Binding Globulin | 1 | 2012 | 1 | 0.020 |
Why?
|
| Triiodothyronine | 1 | 2012 | 54 | 0.020 |
Why?
|
| Sexism | 1 | 2012 | 69 | 0.020 |
Why?
|
| Heart Rate | 1 | 2016 | 849 | 0.020 |
Why?
|
| Thyroxine | 1 | 2012 | 65 | 0.020 |
Why?
|
| Microbiota | 1 | 2019 | 781 | 0.020 |
Why?
|
| Motivation | 1 | 2016 | 601 | 0.020 |
Why?
|
| Semen Preservation | 1 | 2011 | 3 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 167 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 219 | 0.020 |
Why?
|
| Clomiphene | 1 | 2011 | 15 | 0.020 |
Why?
|
| Dosage Forms | 1 | 2011 | 10 | 0.020 |
Why?
|
| Psychometrics | 2 | 2008 | 731 | 0.020 |
Why?
|
| Thyrotropin | 1 | 2012 | 118 | 0.020 |
Why?
|
| Organizational Culture | 1 | 2012 | 160 | 0.020 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2011 | 7 | 0.020 |
Why?
|
| Base Sequence | 2 | 2005 | 2171 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 971 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 257 | 0.020 |
Why?
|
| Endoglin | 1 | 2010 | 19 | 0.020 |
Why?
|
| Social Environment | 1 | 2012 | 253 | 0.020 |
Why?
|
| Arylsulfotransferase | 1 | 2010 | 3 | 0.020 |
Why?
|
| Sulfotransferases | 1 | 2010 | 6 | 0.020 |
Why?
|
| Metabolic Equivalent | 1 | 2010 | 3 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2010 | 37 | 0.020 |
Why?
|
| New England | 1 | 2010 | 37 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 2896 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 308 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 1098 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2010 | 54 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2010 | 141 | 0.020 |
Why?
|
| Sperm Count | 1 | 2009 | 21 | 0.020 |
Why?
|
| Tocolytic Agents | 1 | 2009 | 16 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2007 | 1809 | 0.020 |
Why?
|
| Spouse Abuse | 2 | 2000 | 40 | 0.020 |
Why?
|
| Magnesium Sulfate | 1 | 2009 | 18 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2009 | 10 | 0.020 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2009 | 17 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2009 | 9 | 0.020 |
Why?
|
| Risk | 2 | 2002 | 910 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1762 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 49 | 0.020 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2010 | 106 | 0.020 |
Why?
|
| Emergency Medical Services | 2 | 2011 | 694 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2010 | 191 | 0.020 |
Why?
|
| Fetal Death | 1 | 2009 | 58 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2009 | 96 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2014 | 474 | 0.020 |
Why?
|
| Ethinyl Estradiol | 1 | 2008 | 16 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2009 | 164 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2009 | 247 | 0.020 |
Why?
|
| Pelvic Floor | 1 | 2009 | 32 | 0.020 |
Why?
|
| Plant Bark | 1 | 2008 | 11 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 122 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2008 | 125 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 425 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2002 | 1300 | 0.020 |
Why?
|
| Acrosome | 1 | 2008 | 6 | 0.020 |
Why?
|
| Sperm Capacitation | 1 | 2008 | 12 | 0.020 |
Why?
|
| China | 2 | 2000 | 269 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2009 | 117 | 0.020 |
Why?
|
| Dementia | 1 | 2012 | 304 | 0.020 |
Why?
|
| Minerals | 1 | 2008 | 48 | 0.020 |
Why?
|
| Social Support | 1 | 2012 | 647 | 0.020 |
Why?
|
| Neurotic Disorders | 1 | 2007 | 7 | 0.020 |
Why?
|
| Olfactory Mucosa | 1 | 2008 | 38 | 0.020 |
Why?
|
| Proteins | 1 | 2014 | 1011 | 0.020 |
Why?
|
| Drug Costs | 1 | 2009 | 116 | 0.020 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2007 | 12 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2007 | 37 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2008 | 131 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2007 | 79 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2008 | 138 | 0.020 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2007 | 1 | 0.020 |
Why?
|
| Cell Line | 2 | 2004 | 2821 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 396 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 552 | 0.020 |
Why?
|
| Androsterone | 1 | 2007 | 2 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 193 | 0.020 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2007 | 65 | 0.020 |
Why?
|
| Tyrosine | 1 | 2008 | 219 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 507 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 392 | 0.020 |
Why?
|
| Global Health | 1 | 2010 | 401 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2009 | 338 | 0.020 |
Why?
|
| Energy Intake | 1 | 2010 | 500 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 112 | 0.020 |
Why?
|
| Stillbirth | 1 | 2007 | 79 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2008 | 132 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 166 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2005 | 1465 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2008 | 192 | 0.020 |
Why?
|
| Arthralgia | 1 | 2007 | 61 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2007 | 199 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 168 | 0.020 |
Why?
|
| Body Height | 1 | 2007 | 199 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 280 | 0.010 |
Why?
|
| Streptococcus agalactiae | 1 | 2008 | 109 | 0.010 |
Why?
|
| Outpatients | 1 | 2010 | 444 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2014 | 1174 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2009 | 479 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2008 | 243 | 0.010 |
Why?
|
| Reproductive History | 1 | 2005 | 12 | 0.010 |
Why?
|
| Leptin | 1 | 2007 | 247 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2006 | 167 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2005 | 27 | 0.010 |
Why?
|
| Androstenedione | 1 | 2005 | 10 | 0.010 |
Why?
|
| Sperm Tail | 1 | 2005 | 8 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1699 | 0.010 |
Why?
|
| Streptococcal Infections | 1 | 2008 | 170 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2009 | 528 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 430 | 0.010 |
Why?
|
| U937 Cells | 1 | 2004 | 27 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2005 | 368 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2004 | 156 | 0.010 |
Why?
|
| Luciferases | 1 | 2004 | 152 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2004 | 88 | 0.010 |
Why?
|
| Prothrombin | 1 | 2004 | 24 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 1178 | 0.010 |
Why?
|
| Safety | 1 | 2006 | 354 | 0.010 |
Why?
|
| Tissue Polypeptide Antigen | 1 | 2004 | 2 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 709 | 0.010 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2004 | 18 | 0.010 |
Why?
|
| Leydig Cells | 1 | 2004 | 15 | 0.010 |
Why?
|
| Steroidogenic Factor 1 | 1 | 2004 | 12 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2004 | 55 | 0.010 |
Why?
|
| Membranes | 1 | 2004 | 13 | 0.010 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2008 | 300 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2007 | 781 | 0.010 |
Why?
|
| Granulosa Cells | 1 | 2004 | 33 | 0.010 |
Why?
|
| Mass Screening | 1 | 2012 | 1347 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2008 | 1702 | 0.010 |
Why?
|
| Physicians | 1 | 2012 | 948 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2005 | 608 | 0.010 |
Why?
|
| Midwestern United States | 1 | 2003 | 45 | 0.010 |
Why?
|
| Stem Cells | 1 | 2008 | 621 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 506 | 0.010 |
Why?
|
| Psychology | 1 | 2004 | 88 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 886 | 0.010 |
Why?
|
| Body Weight | 1 | 2007 | 968 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2004 | 245 | 0.010 |
Why?
|
| Demography | 1 | 2003 | 287 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 409 | 0.010 |
Why?
|
| Gonorrhea | 1 | 2003 | 63 | 0.010 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2002 | 34 | 0.010 |
Why?
|
| Michigan | 1 | 2002 | 136 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2002 | 22 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2005 | 429 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2004 | 245 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2008 | 1017 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2007 | 807 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2005 | 419 | 0.010 |
Why?
|
| Extraembryonic Membranes | 1 | 2001 | 5 | 0.010 |
Why?
|
| Phytoestrogens | 1 | 2001 | 17 | 0.010 |
Why?
|
| Isoflavones | 1 | 2001 | 25 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 1152 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2002 | 193 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 549 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 1474 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2002 | 143 | 0.010 |
Why?
|
| Organization and Administration | 1 | 2001 | 14 | 0.010 |
Why?
|
| Body Constitution | 1 | 2001 | 51 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2001 | 272 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 741 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 507 | 0.010 |
Why?
|
| Patient Participation | 1 | 2004 | 428 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 1029 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2002 | 276 | 0.010 |
Why?
|
| Substance-Related Disorders | 2 | 2000 | 1085 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 881 | 0.010 |
Why?
|
| Dizziness | 1 | 2001 | 101 | 0.010 |
Why?
|
| North Dakota | 1 | 1999 | 6 | 0.010 |
Why?
|
| Models, Neurological | 1 | 2001 | 250 | 0.010 |
Why?
|
| Apolipoproteins B | 1 | 1999 | 47 | 0.010 |
Why?
|
| Apolipoprotein A-I | 1 | 1999 | 39 | 0.010 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2001 | 154 | 0.010 |
Why?
|
| Transfection | 1 | 2001 | 922 | 0.010 |
Why?
|
| Lipoproteins, LDL | 1 | 1999 | 119 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 1999 | 99 | 0.010 |
Why?
|
| Lipoprotein(a) | 1 | 1999 | 69 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 4525 | 0.010 |
Why?
|
| Hypertension | 1 | 2007 | 1259 | 0.010 |
Why?
|
| Neurons | 1 | 2008 | 1637 | 0.010 |
Why?
|
| Benzene | 1 | 1998 | 18 | 0.010 |
Why?
|
| Cholesterol | 1 | 1999 | 402 | 0.010 |
Why?
|
| Hydrogen Sulfide | 1 | 1998 | 48 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2001 | 483 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2000 | 317 | 0.010 |
Why?
|
| Health Policy | 1 | 2000 | 398 | 0.010 |
Why?
|
| Maternal Exposure | 1 | 1998 | 184 | 0.010 |
Why?
|
| Melanoma | 1 | 2001 | 757 | 0.010 |
Why?
|